Tanaka Hiromitsu, Nishida-Fukuda Hisayo, Wada Morimasa, Tokuhiro Keizo, Matsushita Hiroaki, Ando Yukio
Faculty of Pharmaceutical Sciences, Nagasaki International University, Huis Ten Bosch, Sasebo, Nagasaki, Japan. Email:
Department of Genome Editing, Institute of Biomedical Science, Kansai Medical University, Shin-machi, Hirakata City, Osaka, Japan.
Cell J. 2022 Apr;24(4):212-214. doi: 10.22074/cellj.2022.7796. Epub 2022 Apr 27.
HASPIN acts in chromosome segregation via histone phosphorylation. Recently, HASPIN inhibitors have been shown to suppress growth of various cancer cells. Pancreatic cancer has no symptom in the early stages and may progress before detection. So, the 5-year survival rate is low. Here, we reported that administration of the HASPIN inhibitor, CHR-6494, to mice bearing pancreatic BxPC-3-Luc cancer cells significantly suppressed growth of BxPC-3-Luc cells. CHR-6494 might be a useful agent for treating pancreatic cancer.
HASPIN通过组蛋白磷酸化作用于染色体分离。最近，HASPIN抑制剂已被证明可抑制多种癌细胞的生长。胰腺癌在早期没有症状，可能在被发现之前就已进展。因此，其5年生存率较低。在此，我们报道了给携带胰腺BxPC-3-Luc癌细胞的小鼠施用HASPIN抑制剂CHR-6494可显著抑制BxPC-3-Luc细胞的生长。CHR-6494可能是一种治疗胰腺癌的有效药物。
Zotero 插件
